Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Chief Executive Succession

18 Nov 2024 07:00

RNS Number : 5858M
Elementis PLC
18 November 2024
 

18 November 2024

 

Elementis plc

Chief Executive Succession

Elementis plc (the "Company"), today announces that, following a period of discussion, Paul Waterman has agreed with the Board that it is the right time to transition the leadership of Elementis to a new Chief Executive Officer, following his nine years of service. Paul has agreed to remain with the Company until a successor is appointed, and will step down no later than the Company's Annual General Meeting in April 2025, remaining available as required for any transition or other support until the end of July 2025.

The Board has initiated a process to identify and appoint a successor, and a further announcement in relation to this will be made in due course.

Paul Waterman, CEO of the Company, said:

"Over the past nine years it has been my privilege to lead Elementis as we have transformed the group into a higher quality, more focused specialty chemicals business. The Company is now well positioned for future success as a result of our focused strategy implementation and the commitment of a very talented Elementis team. I am confident that performance will further improve through 2025 and 2026, making now an appropriate time for a leadership transition."

John O'Higgins, Chair of the Company, said:

"On behalf of the Board, I should like to thank Paul for his long tenure of leadership of Elementis and we wish him the very best for the future. He will be leaving the Company in a strong strategic and financial position and with many exciting opportunities ahead."

This announcement is made in accordance with UK Listing Rule 6.4.6.

This announcement contains inside information. The person responsible for the release of this announcement on behalf of the Company is Anna Lawrence, Group General Counsel and Company Secretary.

Notes:

Paul Waterman will be treated in accordance with the Company's Remuneration Policy and his service agreement for the remaining term of his contract. Full details will be disclosed on the Company's website in compliance with Section 430(2B) of the Companies Act 2006 in due course, and in the Directors' Remuneration Report within the Company's Annual Reports for the years ended 31 December 2024 and 31 December 2025.

 

Enquiries:

Eva Hatfield, Head of Investor Relations 07553 340380

 

Media:

Martin Robinson/Olivia Peters, Teneo 020 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABRBJTMTMBTPI
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.